Translational medicine is bench-to-bedside. This was indeed translational research. This kind of medicine seems more like bedside-to-bedside, as in giving the

Translational medicine is bench-to-bedside. This was indeed translational research. This kind of medicine seems more like bedside-to-bedside, as in giving the cancer guy's drug to the Parkinson's guy in the next bed over and seeing what happens. But actually there's some animal model research behind it from the same people in 2013, so they definitely did their mouse-homework and hopefully it will continue to show promise in larger trials. From their 2013 paper's abstract: "Here, we show that lentiviral expression of α-synuclein in the mouse SN leads to Abl activation (phosphorylation) and lentiviral Abl expression increases α-synuclein levels, in agreement with Abl activation in PD brains. Administration of the tyrosine kinase inhibitor nilotinib decreases Abl activity and ameliorates autophagic clearance of α-synuclein in transgenic and lentiviral gene transfer models." http://hmg.oxfordjournals.org/content/early/2013/05/09/hmg.ddt192.abstract http://hmg.oxfordjournals.org/content/early/2013/05/09/hmg.d...